UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 26.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 104,855 shares of the company's stock after purchasing an additional 21,781 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.23% of Pacira BioSciences worth $1,975,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently added to or reduced their stakes in the company. Sterling Capital Management LLC increased its stake in Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after purchasing an additional 1,208 shares in the last quarter. Ancora Advisors LLC purchased a new position in shares of Pacira BioSciences in the fourth quarter valued at $26,000. PNC Financial Services Group Inc. increased its position in shares of Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after buying an additional 513 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Pacira BioSciences during the 4th quarter worth $103,000. Finally, State of Wyoming grew its stake in Pacira BioSciences by 8.0% in the 4th quarter. State of Wyoming now owns 6,566 shares of the company's stock valued at $124,000 after acquiring an additional 487 shares during the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.
Wall Street Analyst Weigh In
PCRX has been the topic of several recent research reports. Wall Street Zen raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a report on Friday. HC Wainwright upped their target price on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. Barclays raised their price target on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Finally, Needham & Company LLC reduced their price objective on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $26.44.
View Our Latest Stock Report on Pacira BioSciences
Pacira BioSciences Trading Down 2.1%
Shares of Pacira BioSciences stock traded down $0.55 during trading hours on Monday, hitting $25.42. The company's stock had a trading volume of 552,134 shares, compared to its average volume of 973,200. The business has a fifty day moving average of $25.53 and a 200 day moving average of $23.41. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $29.95. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $1.18 billion, a PE ratio of -12.52 and a beta of 0.52.
Insider Transactions at Pacira BioSciences
In other Pacira BioSciences news, SVP Lauren Riker sold 5,578 shares of the stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total transaction of $146,199.38. Following the transaction, the senior vice president now owns 59,564 shares of the company's stock, valued at $1,561,172.44. This trade represents a 8.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 6.40% of the company's stock.
Pacira BioSciences Profile
(
Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Further Reading
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
